Bibliographic Details
| Title: |
A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy). |
| Authors: |
Mills, Jeremy |
| Source: |
Issues in Mental Health Nursing. Dec2024, Vol. 45 Issue 12, p1364-1367. 4p. |
| Subjects: |
Drug therapy for schizophrenia, Combination drug therapy, Blood-brain barrier, Antipsychotic agents, United States. Food & Drug Administration, Drug approval, Pharmacy information services, Dopamine antagonists, Muscarinic antagonists, Drug development, Psychopharmacology, Muscarinic agonists, Therapeutics, Pharmacodynamics |
| Abstract: |
The article discusses the groundbreaking approval of a new antipsychotic medication, Cobenfy (xanomeline and trospium), which marks a significant shift in the treatment of schizophrenia by targeting acetylcholine instead of dopamine. This approval represents a major departure from traditional antipsychotics, which have predominantly focused on dopaminergic mechanisms. |
| Database: |
Psychology and Behavioral Sciences Collection |
